Description
SWOT ANALYSIS OF UCB PHARMACEUTICALS
UCB Pharmaceuticals
Parent Company
UCB Pharmaceuticals
Category
Pharmaceutical
Sector
Healthcare
Tagline/ Slogan
Aspiring to be patient centric biopharma leader
It is global biopharma focused on severe diseases with operations in USP over 40 countries
STP
Segment
Central nervous system diseases & immunology
Healthcare professionals offering solutions to patients suffering from Target Group severe diseases
A global biopharma focused in severe diseases focused in two areas Positioning namely CNS & immunology
SWOT Analysis
1. UCB has nearly 9000 well trained employees 2. Strong global presence in over 40 countries 3. It has strong product pipeline with many molecules in last stages of development especially in case of CNS 4. They have four major blockbuster products such as Cimzia, Vimpat, Strength Neutro, Keppra.
1. Company operates in limited segments of medication for severe diseases only 2. It has limited presence in developing world as majority of revenue Weakness comes from America & Europe operations
1. There is good scope for development of new treatment options in epilepsy 2. they can further utilize full potential of their blockbuster drugs Opportunity 3. Increasing awareness about severe diseases
1. Economic instability of euro zone can hurt revenue of company 2. Strong FDA drug development guidelines 3. Increasing competition of other pharma majors in their business Threats segments
Competition
1. Abbott laboratories 2. Amgen 3. AstraZeneca Competitors 4. Forest laboratories
doc_364328320.docx
SWOT ANALYSIS OF UCB PHARMACEUTICALS
UCB Pharmaceuticals
Parent Company
UCB Pharmaceuticals
Category
Pharmaceutical
Sector
Healthcare
Tagline/ Slogan
Aspiring to be patient centric biopharma leader
It is global biopharma focused on severe diseases with operations in USP over 40 countries
STP
Segment
Central nervous system diseases & immunology
Healthcare professionals offering solutions to patients suffering from Target Group severe diseases
A global biopharma focused in severe diseases focused in two areas Positioning namely CNS & immunology
SWOT Analysis
1. UCB has nearly 9000 well trained employees 2. Strong global presence in over 40 countries 3. It has strong product pipeline with many molecules in last stages of development especially in case of CNS 4. They have four major blockbuster products such as Cimzia, Vimpat, Strength Neutro, Keppra.
1. Company operates in limited segments of medication for severe diseases only 2. It has limited presence in developing world as majority of revenue Weakness comes from America & Europe operations
1. There is good scope for development of new treatment options in epilepsy 2. they can further utilize full potential of their blockbuster drugs Opportunity 3. Increasing awareness about severe diseases
1. Economic instability of euro zone can hurt revenue of company 2. Strong FDA drug development guidelines 3. Increasing competition of other pharma majors in their business Threats segments
Competition
1. Abbott laboratories 2. Amgen 3. AstraZeneca Competitors 4. Forest laboratories
doc_364328320.docx